TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Oric Pharmaceuticals
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025

ORIC Pharmaceuticals presented promising Phase 1b trial results for enozertinib, a potential treatment for non-small cell lung cancer (NSCLC) with EGFR mutations, showing strong systemic and CNS activity with favorable safety profile.

Insights
ORIC   positive

Demonstrated strong preliminary results with 80% overall response rate in first-line NSCLC patients, 100% intracranial response rate, and no significant off-target toxicities, indicating promising drug development progress